Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: Implications for vaccine design

Journal of Immunology

Volumn 198, Issue 10, 2017, Pages 4012-4024

  Pepini, Timothy ^a   Pulichino, Anne Marie ^b,d   Carsillo, Thomas ^c   Carlson, Alicia L ^c   Sari Sarraf, Farid ^c   Ramsauer, Katrin ^b,e   Debasitis, Jason C ^b,f   Maruggi, Giulietta ^a   Otten, Gillis R ^b,g   Geall, Andrew J ^b,h   Yu, Dong ^a   Ulmer, Jeffrey B ^a   Iavarone, Carlo ^a  

^a GLAXOSMITHKLINE   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d LAVAL UNIVERSITY   (Canada)

^e Themis Bioscience GmbH   (Austria)

^f SYNEOS HEALTH   (United States)

^g Seqirus Pharmaceuticals Inc   (United States)

^h AVID Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON RECEPTOR; RNA VACCINE; SELF AMPLIFYING MRNA VACCINE; UNCLASSIFIED DRUG; ANTIGEN; IMMUNOLOGICAL ADJUVANT; MESSENGER RNA; VACCINE; VIRUS ANTIBODY; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; EMBRYO; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOSTIMULATION; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; CHEMISTRY; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; THREE DIMENSIONAL IMAGING; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS; DRUG DESIGN; IMAGING, THREE-DIMENSIONAL; INTERFERON TYPE I; MICE; RESPIRATORY SYNCYTIAL VIRUSES; RNA, MESSENGER; RNA, VIRAL; VACCINATION; VACCINE POTENCY; VIRAL VACCINES;

EID: 85019702720     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1601877     Document Type: Article

References (44)

1. Geall, A. J., C. W. Mandl, and J. B. Ulmer. 2013. RNA: The new revolution in nucleic acid vaccines. Semin. Immunol. 25: 152-159.
2. Ulmer, J. B., and A. J. Geall. 2016. Recent innovations in mRNA vaccines. Curr. Opin. Immunol. 41: 18-22.
3. Rayner, J. O., S. A. Dryga, and K. I. Kamrud. 2002. Alphavirus vectors and vaccination. Rev. Med. Virol. 12: 279-296.
4. Fleeton, M. N., M. Chen, P. Berglund, G. Rhodes, S. E. Parker, M. Murphy, G. J. Atkins, and P. Liljeström. 2001. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J. Infect. Dis. 183: 1395-1398.
5. Iwasaki, A., and R. Medzhitov. 2015. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16: 343-353.
6. Pasare, C., and R. Medzhitov. 2005. Control of B-cell responses by Toll-like receptors. Nature 438: 364-368.
7. Guy, B. 2007. The perfect mix: Recent progress in adjuvant research. Nat. Rev. Microbiol. 5: 505-517.
8. Hoebe, K., and B. Beutler. 2008. Forward genetic analysis of TLR-signaling pathways: An evaluation. Adv. Drug Deliv. Rev. 60: 824-829.
9. Iavarone, C., K. Ramsauer, A. V. Kubarenko, J. C. Debasitis, I. Leykin, A. N. Weber, O. M. Siggs, B. Beutler, P. Zhang, G. Otten, et al. 2011. A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding. J. Immunol. 186: 4213-4222.
10. Geall, A. J., A. Verma, G. R. Otten, C. A. Shaw, A. Hekele, K. Banerjee, Y. Cu, C. W. Beard, L. A. Brito, T. Krucker, et al. 2012. Nonviral delivery of selfamplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 109: 14604-14609.
11. Tomar, S., R. W. Hardy, J. L. Smith, and R. J. Kuhn. 2006. Catalytic core of alphavirus nonstructural protein nsP4 possesses terminal adenylyltransferase activity. J. Virol. 80: 9962-9969.
12. Donnelly, M. L., L. E. Hughes, G. Luke, H. Mendoza, E. ten Dam, D. Gani, and M. D. Ryan. 2001. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Virol. 82: 1027-1041.
13. Heyes, J., L. Palmer, K. Bremner, and I. MacLachlan. 2005. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107: 276-287.
14. Perri, S., C. E. Greer, K. Thudium, B. Doe, H. Legg, H. Liu, R. E. Romero, Z. Tang, Q. Bin, T. W. Dubensky, Jr., et al. 2003. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77: 10394-10403.
15. Swanson, K.A., E. C. Settembre, C. A. Shaw, A. K. Dey,R.Rappuoli, C.W. Mandl, P. R. Dormitzer, and A. Carfi. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc. Natl. Acad. Sci. USA 108: 9619-9624.
16. Loo, Y. M., J. Fornek, N. Crochet, G. Bajwa, O. Perwitasari, L. Martinez- Sobrido, S. Akira, M. A. Gill, A. García-Sastre, M. G. Katze, and M. Gale, Jr. 2008. Distinct RIG-I and MDA5 signaling by RNAviruses in innate immunity. J. Virol. 82: 335-345.
17. Smyth, G. K. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3: Article3.
18. Huang da, W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4: 44-57.
19. Huang da, W., B. T. Sherman, and R. A. Lempicki. 2009. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37: 1-13.
20. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
21. Szymczak-Workman, A. L., K. M. Vignali, and D. A. Vignali. 2012. Design and construction of 2A peptide-linked multicistronic vectors. Cold Spring Harb. Protoc. 2012: 199-204.
22. Greenland, J. R., R. Geiben, S. Ghosh, W. A. Pastor, and N. L. Letvin. 2007. Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis. J. Immunol. 178: 5652-5658.
23. Borish, L. C., and J. W. Steinke. 2003. 2. Cytokines and chemokines. J. Allergy Clin. Immunol. 111(Suppl.): S460-S475.
24. Broz, P., and D. M. Monack. 2013. Newly described pattern recognition receptors team up against intracellular pathogens. Nat. Rev. Immunol. 13: 551-565.
25. Cervantes, J. L., B. Weinerman, C. Basole, and J. C. Salazar. 2012. TLR8: The forgotten relative revindicated. Cell. Mol. Immunol. 9: 434-438.
26. Forsbach, A., C. Müller, C. Montino, A. Kritzler, R. Curdt, A. Benahmed, M. Jurk, and J. Vollmer. 2012. Impact of delivery systems on siRNA immune activation and RNA interference. Immunol. Lett. 141: 169-180.
27. Forsbach, A., J. G. Nemorin, C. Montino, C. Müller, U. Samulowitz, A. P. Vicari, M. Jurk, G. K. Mutwiri, A. M. Krieg, G. B. Lipford, and J. Vollmer. 2008. Identification of RNA sequence motifs stimulating sequence-specific TLR8- dependent immune responses. J. Immunol. 180: 3729-3738.
28. Karikó, K., M. Buckstein, H. Ni, and D. Weissman. 2005. Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165-175.
29. Hamm, S., E. Latz, D. Hangel, T. Müller, P. Yu, D. Golenbock, T. Sparwasser, H. Wagner, and S. Bauer. 2010. Alternating 29-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist. Immunobiology 215: 559-569.
30. Alexopoulou, L., A. C. Holt, R. Medzhitov, and R. A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
31. Schlee, M. 2013. Master sensors of pathogenic RNA - RIG-I like receptors. Immunobiology 218: 1322-1335.
32. Sheehan, K. C., K. S. Lai, G. P. Dunn, A. T. Bruce, M. S. Diamond, J. D. Heutel, C. Dungo-Arthur, J. A. Carrero, J. M. White, P. J. Hertzog, and R. D. Schreiber. 2006. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26: 804-819.
33. Kim, B. H., A. R. Shenoy, P. Kumar, C. J. Bradfield, and J. D. MacMicking. 2012. IFN-inducible GTPases in host cell defense. Cell Host Microbe 12: 432-444.
34. Zhao, C., M. N. Collins, T. Y. Hsiang, and R. M. Krug. 2013. Interferon-induced ISG15 pathway: An ongoing virus-host battle. Trends Microbiol. 21: 181-186.
35. Mattijssen, S., and G. J. Pruijn. 2012. Viperin, a key player in the antiviral response. Microbes Infect. 14: 419-426.
36. Najjar, I., and R. Fagard. 2010. STAT1 and pathogens, not a friendly relationship. Biochimie 92: 425-444.
37. Fotin-Mleczek, M., K. M. Duchardt, C. Lorenz, R. Pfeiffer, S. Ojkić-Zrna, J. Probst, and K. J. Kallen. 2011. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34: 1-15.
38. Saito, T., and M. Gale, Jr. 2007. Principles of intracellular viral recognition. Curr. Opin. Immunol. 19: 17-23.
39. Pichlmair, A., and C. Reis e Sousa. 2007. Innate recognition of viruses. Immunity 27: 370-383.
40. Pollard, C., J. Rejman, W. De Haes, B. Verrier, E. Van Gulck, T. Naessens, S. De Smedt, P. Bogaert, J. Grooten, G. Vanham, and S. De Koker. 2013. Type I IFN counteracts the induction of antigen-specific immune responses by lipidbased delivery of mRNA vaccines. Mol. Ther. 21: 251-259.
41. Cruz, C. C., M. S. Suthar, S. A. Montgomery, R. Shabman, J. Simmons, R. E. Johnston, T. E. Morrison, and M. T. Heise. 2010. Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein. Virology 399: 1-10.
42. Maruggi, G., C. A. Shaw, G. R. Otten, P. W. Mason, and C. W. Beard. 2013. Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity. Virology 447: 254-264.
43. Kamrud, K. I., M. Custer, J. M. Dudek, G. Owens, K. D. Alterson, J. S. Lee, J. L. Groebner, and J. F. Smith. 2007. Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 360: 376-387.
44. Trinchieri, G. 2010. Type I interferon: Friend or foe? J. Exp. Med. 207: 2053-2063.